Market Overview:
Bronchiectasis drugs are used to treat bacterial infections associated with bronchiectasis and loosen mucus to improve lung function. Common drug classes include antibiotics, bronchodilators, mucolytics and anti-inflammatory drugs. Bronchiectasis drugs help reduce symptoms, prevent disease progression and exacerbations.
Market key trends:
Rising adoption of combination therapies for bronchiectasis treatment is driving market growth. Combination therapies involve administering two or more drugs together that act by different mechanisms to achieve better treatment outcomes compared to monotherapy. For example, combining antibiotics with bronchodilators or mucolytics provides additional therapeutic benefits. Increasing research into targeted biologic therapies is also fueling the market. Biologics help modulate the underlying inflammatory processes associated with bronchiectasis. Additionally, growing bronchiectasis patient population due to rising incidence of chronic respiratory diseases and aging population is boosting demand for therapeutic drugs. Moreover, improvements in diagnosis and awareness are identifying more bronchiectasis cases, thereby expanding the customer base for drugs.
Porter’s Analysis
Threat of new entrants: The biopharmaceutical companies require high capital and expertise to enter into the bronchiectasis drugs market making it difficult for new players to enter.
Bargaining power of buyers: The bargaining power of buyers is moderate as the treatment of bronchiectasis is usually long term making patients dependent on available drugs in the market.
Bargaining power of suppliers: The bargaining power of suppliers is low due to availability of generic substitutes and presence of many pharmaceutical companies in the market.
Threat of new substitutes: The threat of new substitutes is high as research is ongoing for development of novel therapeutics.
Competitive rivalry: Intense due to presence of many players.
SWOT Analysis
Strength: Wide range of treatment options available, growing awareness about disease.
Weakness: Lack of approved drugs to treat the underlying causes, high costs associated with treatment.
Opportunity: Rising bronchiectasis prevalence, ongoing clinical trials evaluating new drugs.
Threats: Stringent regulatory pathways, patent expiries of major drugs.
The global Bronchiectasis Drugs Market Demand is estimated to be valued at US$ 303.8 Mn in 2023 and is expected to exhibit a CAGR of 10 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Key Takeaways
The global bronchiectasis drugs market is expected to witness high growth at a CAGR of 10% over the forecast period, due to increasing bronchiectasis disease prevalence worldwide driven by rising cigarette smoking and air pollution.
Regionally, North America is expected to dominate the global market due to high research activities and availability of advanced treatment facilities in the US and Canada. The Asia Pacific region is anticipated to exhibit the fastest growth over the coming years due to growing patient pool and improving healthcare infrastructure across developing nations.
Key players operating in the bronchiectasis drugs market are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Sanofi S.A., Sunovion Pharmaceuticals Inc., Mylan N.V., Cipla Ltd., Grifols S.A., Insmed Incorporated, and Arbor Pharmaceuticals LLC. The market is fairly consolidated with top players accounting for majority share.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
